

**Anthem Biosciences Limited**

(Formerly known as Anthem Biosciences Pvt. Ltd.)

49, F1 & F2, Canara Bank Road,  
Bommasandra Industrial Area, Phase - I  
Bommasandra, Bengaluru - 560 099  
Karnataka, India

CIN : U24233KA2006PLC039703

Tel : +91 80 6672 4000

Fax : +91 80 6672 4020

[www.anthembio.com](http://www.anthembio.com)

Date: August 13, 2025

To,  
BSE Limited,  
20th Floor, P.J. Towers,  
Dalal Street,  
Mumbai - 400001.  
BSE Scrip Code: 544449

National Stock Exchange of India Limited  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex, Bandra (E),  
Mumbai – 400 051  
NSE Scrip Symbol: ANTHEM

**Subject:** Press Release on the Unaudited Consolidated Financial Results for the quarter ended June 30, 2025

Dear Sir/Ma'am

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed a copy of the Press Release on the Unaudited Consolidated Financial Results of the Company for the quarter ended June 30, 2025.

The same is also available on the Company's website at <https://www.anthembio.com/investor.html>.

We request you to kindly take the same on record.

Thanking you,

Yours truly,

For Anthem Biosciences Limited

(Formerly known as Anthem Biosciences Private Limited)

**DIVYA**  
**PRASAD**

Digitally signed by  
DIVYA PRASAD  
Date: 2025.08.13  
21:00:54 +05'30'

**Divya Prasad**

**Company Secretary & Compliance Officer**

**Membership No: A41438**

**Press Release: Anthem Q1FY26 Results**

***Consolidated Revenue from Operations stood at ₹5,402 Mn.***

***EBITDA for the quarter was ₹2,143 Mn.***

***PAT at ₹1,358 Mn, with PAT margins at 24%.***

**Bengaluru, August 13, 2025:** Anthem Biosciences Limited (BSE: 544449 | NSE: ANTHEM | INE0CZ201020), an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (“CRDMO”), today announced consolidated results for the first quarter ended June 30, 2025 as approved by its Board of Directors.

**Q1 FY26 Financial Highlights:**

Particulars (₹ Mn)	Q1FY26	Q1FY25	YoY	Q4FY25	QoQ	FY25
Revenue from Operations	5,402	3,386	59.5%	4,832	11.8%	18,446
<i>CRDMO</i>	4,527	2,655	70.5%	3,923	15.4%	15,061
<i>Specialty Ingredients</i>	875	731	19.7%	909	-3.8%	3,385
Other Income	228	195	17.3%	141	62.2%	857
<b>Total Revenues</b>	<b>5,630</b>	<b>3,580</b>	<b>57.3%</b>	<b>4,973</b>	<b>13.2%</b>	<b>19,303</b>
<b>EBITDA</b>	<b>2,143</b>	<b>1,404</b>	<b>52.7%</b>	<b>2,092</b>	<b>2.4%</b>	<b>7,566</b>
<b>Profit before tax</b>	<b>1,862</b>	<b>1,180</b>	<b>57.9%</b>	<b>1,783</b>	<b>4.5%</b>	<b>6,569</b>
<b>Profit after tax</b>	<b>1,358</b>	<b>824</b>	<b>64.8%</b>	<b>826</b>	<b>64.4%</b>	<b>4,513</b>

- Consolidated Revenue from Operations was ₹5,402 Mn for the quarter
  - CRDMO business delivered ₹4,527 Mn revenues
  - Specialty Ingredients delivered ₹875 Mn revenues
- EBITDA was ₹2,143 Mn, with EBITDA margins at 38%
- PAT (Profit After Tax) was ₹1,358 Mn, with PAT margins at 24%
- Net Cash position as of June 30, 2025, is ₹7,848 Mn

Commenting on the results, **Ajay Bhardwaj, Chairman, Managing Director and CEO, Anthem Biosciences Limited, said:** “We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. Strong YoY (Year on Year) growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25. A combination of a dedicated team, strategic focus, operational excellence and long-standing client partnerships has helped us deliver performance across both CRDMO and Specialty Ingredients business”.

## Earnings Call:

Anthem Biosciences Limited will conduct earnings call at 12 Noon (IST) on August 14, 2025 to discuss the financial and business performance of the quarter. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time.

---

<b>Date and Time</b>	<b>August 14, Thursday, 12:00 – 13:00 (IST) / 14:30 – 15:30 (SGT/HKT)</b>
----------------------	---

<b>Universal Dial-in</b>	+91 22 6280 1548 / +91 22 7115 8376
--------------------------	-------------------------------------

<b>International Dial-in</b>	Singapore: 8001012045   HK: 800964448   Japan: 00531161110   UK: 08081011573
------------------------------	--

<b>Diamond Pass link</b>	<a href="#">Diamond Pass Registration</a>
--------------------------	---

---

**About Anthem:** Incorporated in Bangalore on June 13, 2006, Anthem is an innovation-driven and technology-focused CRDMO with fully integrated operations spanning across drug discovery, development and manufacturing. Anthem is one of the few companies in India with integrated New Chemical Entity (“NCE”) and New Biological Entity (“NBE”) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, Anthem serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally. With the three pillars of innovation and technology, high quality standards, and a customer-first approach, Anthem is committed to solving problems in biology and chemistry using technology.

For more information, please visit  
<https://anthembio.com/investor.html>

For further details, please feel free to contact:  
[investors.abl@anthembio.com](mailto:investors.abl@anthembio.com) | [anthem@adfactorspr.com](mailto:anthem@adfactorspr.com)

---

*Disclaimer: This press release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects on the Company. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, change in laws and regulations that apply to pharmaceuticals, increasing competition in and changes in political conditions in India. Neither Anthem, nor our directors, assume any obligation to update any forward-looking statement contained in this release. The Company undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements*